| Name | Title | Contact Details |
|---|
AS&D is a premier US-based designer, manufacturer, and distributor of aluminum railing, balcony, sunshade, and patio cover systems. We sell exclusively to dealers, distributors and wholesalers in the residential and commercial construction industries. We source our aluminum through leading industrial suppliers who use more than 50 percent recycled aluminum in their manufacturing processes. This gives us the competitive advantage to provide environmentally friendly products that are durable, lightweight, and strong. We design our systems to be ready-to-install and easy-to-handle while our in-house inventory allows for rapid order fulfillment and delivery. As a family-owned manufacturer, we prioritize building long-term relationships with our customers, as well as supporting our community locally and nationally.
IMCD Group is a global distributor of specialty chemicals and ingredients, headquartered in Rotterdam, Netherlands. Founded in 1995, the company is listed on the Amsterdam stock exchange and celebrated its 25th anniversary in 2020. IMCD specializes in serving various industries, including pharmaceuticals, food, personal care, coatings, and lubricants, providing formulatory solutions tailored to customer needs. The company has expanded its operations internationally, with significant growth in the Americas, including the establishment of IMCD US in 2015. IMCD Group generates approximately $4.7 billion in revenue and employs around 3,570 people worldwide. Known for its innovative approach and minimal corporate bureaucracy, IMCD maintains strong partnerships with a diverse range of suppliers and customers, from small manufacturers to large corporations.
F1® returns to the Las Vegas Strip November 21-23, 2024!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Polestar Solutions & Services is a global AI and analytics company focused on enterprise transformation through data-driven solutions. Founded by experienced technocrats, the company operates in the U.S. and India, with offices in cities like Dallas, Noida, and Mumbai. With over 600 employees, Polestar is projected to grow by 60% globally in the coming year. The company specializes in AI-powered analytics, serving industries such as consumer packaged goods, retail, manufacturing, and pharmaceuticals. Polestar offers a range of services, including generative AI, data engineering, and advanced analytics platforms. It develops tailored solutions for revenue growth management, supply chain optimization, and customer analytics. Polestar is recognized as a Great Place to Work and has received multiple awards for its growth and excellence in AI and analytics services. Its mission is to empower businesses through intelligent, data-driven transformation.